COMPLETED

Treatment Strategy to Enhance Nrf2 Signaling in Older Adults

Talk to us

Conditions

Aging ProblemsRedoxSulforaphaneNrf2Exercise

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Exercise is the cornerstone of disease prevention and often an important component of treatment. However, the efficacy of an exercise stimulus is reduced with aging. This study will investigate whether adding a treatment with phytonutrients found in cruciferous vegetables can improve the exercise response in older individuals.

Official Title

Treatment Strategy to Enhance Nrf2 Signaling in Older Adults: Combining Acute Exercise With the Phytochemical Sulforaphane

Quick Facts

Study Start:2023-02-09
Study Completion:2025-05-27
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT04848792

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:60 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Men and women, 60 years and older
  2. * Competent to independently give informed consent
  3. * Successful completion of screening
  4. * Maximal oxygen consumption below the 60th percentile based on gender:
  5. * Women: ≤ 21.2 mL/kg/min
  6. * Men: ≤ 30.5 mL/kg/min
  1. * Estrogen supplementation (in any form) within the previous 6 months
  2. * Any medication that could affect outcome measures such as statins, blood pressure medications, or anti-depressives
  3. * Use of anti-oxidant supplements, in excess of standard multi-vitamins (1 tablet/day) and/or any supplements known to target Nrf2 including resveratrol, Protandim, and sulforaphane
  4. * Current smoker
  5. * Body Mass Index (BMI) greater than 33 kg/m2 (Class I Obesity)
  6. * Any chronic illness that could affect outcome measures, including diabetes, liver or renal disease, or cancer (other than skin cancer)
  7. * History of a myocardial infarction within the last 6 months, clinically significant aortic stenosis, use of cardiac defibrillator, or uncontrolled angina
  8. * Clinically significant arrhythmia on a resting EKG or significant EKG changes during the baseline VO2 max test
  9. * Any other condition that would contraindicate maximal exercise testing, including elevated blood pressure at rest (systolic BP \>150 or diastolic BP \>90 mm Hg on at least 2 measurements, at least 10 minutes apart) or musculoskeletal problems

Contacts and Locations

Study Locations (Sites)

Northern Arizona University
Flagstaff, Arizona, 86011
United States

Collaborators and Investigators

Sponsor: Northern Arizona University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-02-09
Study Completion Date2025-05-27

Study Record Updates

Study Start Date2023-02-09
Study Completion Date2025-05-27

Terms related to this study

Keywords Provided by Researchers

  • Redox
  • Sulforaphane
  • Nrf2
  • Exercise

Additional Relevant MeSH Terms

  • Aging Problems